Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys
Authors:
- 1 September 2021
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 49, 100828
Abstract
No abstract availableKeywords
Funding Information
- Istituto di Ricerche Farmacologiche Mario Negri - IRCCS
This publication has 39 references indexed in Scilit:
- Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disordersBlood Reviews, 2016
- What is the future of PEGylated therapies?Expert Opinion on Emerging Drugs, 2015
- Factor VIII Products and Inhibitor Development in Severe Hemophilia ANew England Journal of Medicine, 2013
- Defining ‘Surveillance’ in Drug SafetyDrug Safety, 2012
- EUHASS: The European Haemophilia Safety Surveillance systemThrombosis Research, 2011
- The Value of Patient-Centred Registries in Phase IV Drug SurveillancePharmaceutical Medicine, 2010
- Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3American Journal of Public Health, 2008
- Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood, 2007
- The effect of thalidomide intake during 113 human pregnanciesTeratology, 1973
- THALIDOMIDE AND CONGENITAL ABNORMALITIESThe Lancet, 1961